Yamirka Sanchez Perez
General Practice · Miami, FLNPI 1346741618
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Novo Nordisk at 29.4% of the total. That places this record below the midpoint for general practice clinicians in FL, where the typical reported total is $253.
Across 4 payments — averaging $20.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$24
- Sumitomo Pharma America, Inc.$22
- AstraZeneca$21
- Lilly USA, LLC$16
Across 337 payments — averaging $2712.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$795K
- Novo Nordisk AS$81K
- Lexicon Pharmaceuticals, Inc.$27K
- Teva Pharmaceuticals USA, Inc.$9K
- Biohaven Pharmaceutical Holding Company Ltd.$2K
What the payments were for
- Food & beverage$83100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| AstraZeneca | 1 | $21 |
| Lilly USA, LLC | 1 | $16 |
How this compares
$83 in reported general payments places this provider in the 25th percentile of 6,901 general practice providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 202 | $153,927 |
| JanuviaSitagliptin Phosphate | 107 | $125,359 |
| EntrestoSacubitril/Valsartan | 60 | $58,191 |
| FarxigaDapagliflozin Propanediol | 50 | $42,046 |
| JardianceEmpagliflozin | 23 | $38,773 |
| XareltoRivaroxaban | 28 | $35,085 |
| OzempicSemaglutide | 21 | $19,132 |
| TrulicityDulaglutide | 12 | $16,949 |
| Atrovent HfaIpratropium Bromide | 27 | $15,048 |
| LinzessLinaclotide | 14 | $13,997 |
| MounjaroTirzepatide | 12 | $12,621 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $11,387 |
| BrilintaTicagrelor | 13 | $8,247 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,113 |
| LumiganBimatoprost | 16 | $7,232 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $21 | $50,29363 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $16 | $29,57124 claims |
| Novo NordiskOzempic, Novolog, Novolog Mix 70-30 | $24 | $24,16447 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 6,901 general practice providers in Florida.
Other general practice in Miami
- Idalia AcostaMiami$99K
- Eddie GomezMiami$59K
- Aladino ValienteMiami$24K
- Viviana WaichMiami$20K
- Libia RiosMiami$15K
- Jose CardonaMiami$15K
- Rosa HuguetMiami$15K
- Robert VogelPalm Beach Gardens$1M
- Bruce OuelletteWest Palm Beach$724K
- Caley CasteleinMiami Beach$586K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.